S&P 500
$5,844.61
-1.6%
-$95.85
DJI
41,860.44
-1.9%
-816.80
NASDAQ
$18,872.64
-1.4%
-$270.07
Bitcoin
110,829.00
+4.2%
+4,479.30
AAPL
$202.42
-2.1%
-$4.44
AMZN
$201.35
-1.3%
-$2.72
GOOG
$170.25
+3.0%
+$4.93
META
$635.69
-0.2%
-$1.41
MSFT
$453.22
-1.1%
-$4.95
NVDA
$131.94
-1.8%
-$2.44
TSLA
$334.80
-2.6%
-$9.02
Aligos Therapeutics (NASDAQ: ALGS)
$5.62
(-7.3%)
-$0.44
Price as of May 21, 2025, 3:58 p.m. ET
Aligos Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aligos Therapeutics Company Info
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.